Automated Drug Laboratory in Orbit: Exobiosphere and Outpost Technologies’ Milestone
An automated laboratory designed for studying diseases and drug screening in microgravity has achieved a significant milestone by becoming the first commercial customer of Outpost Technologies’ Space Factories platform. This partnership, announced by Outpost on October 2, involves Exobiosphere’s Orbital High-Throughput System (OHTS), which will be deployed aboard Outpost’s CarryAll spacecraft in 2028.
Objective and Research Benefits
Exobiosphere, based in Luxembourg, is leveraging the OHTS to enhance disease modeling, drug screening, and various orbital biology projects. By utilizing microgravity, they aim to facilitate research and treatment assessments that are not possible on Earth. A crucial aspect of this collaboration is the focus on returning biological samples for further analysis back on Earth, which is essential for validating research findings and progressing towards practical applications.
Kyle Acierno, Exobiosphere’s co-founder and CEO, notes that microgravity offers biological research advantages that far surpass what can be achieved on Earth. He highlights that the demand for orbital experimentation is soaring, exceeding the capacity of the International Space Station (ISS).
Space Factories Platform
Outpost’s Space Factories initiative utilizes reusable CarryAll spacecraft combined with standardized containers to create an efficient research and manufacturing environment. Each customer can customize their research modules while benefiting from a common operational platform that provides essential services, including power and thermal management.
Jason Dunn, co-founder and CEO of Outpost, emphasized their role in supporting Exobiosphere’s scientific initiatives by providing a structured platform for their research to be conducted and results returned efficiently.
Future Prospects
Outpost’s CarryAll vehicles are designed for versatile operations in orbit, capable of accommodating various payloads ranging from small experiment modules to substantial commercial manufacturing setups, emphasizing the planned return of samples and products to Earth.
As the ISS approaches its scheduled decommissioning in 2030, commercial platforms like Outpost’s are emerging to bridge the gap for researchers needing access to space and subsequent analysis on Earth. The collaboration between Exobiosphere and Outpost represents a significant step forward in space-based biotechnology, signaling a new era of research possibilities beyond our planet.
